# **Title: Salivary IgG antibody response against SARS-CoV-2 differs between vaccinated children and adults**  4 **Author names and affiliations:** María Noel Badano<sup>1</sup>, Irene Keitelman<sup>1</sup>, Matías Javier Pereson<sup>1</sup>, Natalia Aloisi<sup>2</sup>, Florencia Sabbione<sup>1</sup>, Patricia Baré<sup>1,2</sup> 7<sup>1</sup> Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina. Postal address: J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina. 10 <sup>2</sup> Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina. Postal address: J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina. **Correspondence**: María Noel Badano, Laboratorio de Patogenia de Infecciones Virales, Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA 1425, [noebadano@yahoo.com.ar,](mailto:noebadano@yahoo.com.ar) +5491167586135. ORCID identifier: 0000-0002-0358-7738. **Data availability statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request. **Funding/Support:** This study was supported by a grant from CONICET (PIP 11220210100378CO). **Conflict of Interest Disclosure:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. **Ethics Statement:** This study was approved by the Academia Nacional de Medicina Ethics Committee. **Consent Statement:** Written informed consent was obtained from adult participants and from parents for children participants. **Abbreviations:** binding antibody units (BAU) per mL (BAU/mL), geometric mean concentrations (GMC), 95% confidence intervals (95% CI).

## **Abstract**







### **Materials and methods**

### *Study Design, Participants and Samples*



study started at the beginning of the pandemic among healthcare workers from the Academia

Nacional de Medicina, to study the humoral immune response against SARS-CoV-2 after

vaccination and/or infection. The results of the children included in this work are part of an

observational cohort study started on February 2022 to analyze the prevalence of salivary anti-

SARS-CoV-2 IgG antibodies in children.

Blood and saliva sample pairs (*n* = 101) from adults who had received the primary vaccination

schedule and a booster dose were collected between December 2021-November 2022. Saliva

samples (*n* = 80) from children up to 18 years old who had received two or three vaccine doses

were collected between February-August 2022. The median time between last exposure to SARS-

CoV-2 antigens (through vaccination, infection or exposure) and sample collection for all samples

was 58 (21-270), for adult samples was 50 (21-234) and for children's samples was 77 (21−270)

days (Table 1).

In both adults and children, samples were obtained from unexposed individuals and from those who

were exposed to SARS-CoV-2 at any stage of vaccination. Exposed subjects included those with

confirmed past SARS-CoV-2 infection and those who were household contacts. All subjects with

confirmed past SARS-CoV-2 infection had mild disease based on the World Health Organization

classification [23]. Among adults, 49/101 had a confirmed past SARS-CoV-2 infection, 3/101 were

household contacts and 49/101 were unexposed subjects. 11/49 of the infected subjects and 3/3

household contacts were exposed before the Omicron variant circulated in Argentina. The

remaining 38/49 subjects were infected when the only circulating variant in Argentina was





188 a value of  $p < 0.05$  was considered indicative of a significant difference.

### **Results**

#### **IgG specific salivary and blood antibody responses in vaccinated adults**

- 
- Specific antibodies were detected in 100% of blood samples (GMC BAU/mL, 95% CI: 3154,
- 2461−4043) and in 82% of saliva samples (GMC BAU/mL, 95% CI: 67.0, 42.8−104.7). Subjects
- 198 with higher systemic antibody levels  $(\geq$ GMC: 3154 BAU/mL) also showed higher salivary antibody
- concentrations than those with lower systemic antibody levels (GMC BAU/mL, 95% CI, Saliva:
- 200 156.8, 92.7−265.2 *vs* 24.2, 11.1−52.7; *p* < 0.001). Furthermore, higher systemic antibody levels
- were found in subjects with detectable salivary antibodies compared to those without detectable
- salivary antibodies (GMC BAU/mL, 95% CI, Blood: 3841, 2979−4952 *vs* 1316, 701.1−2469; *p*
- 0.01) (Figure 1A-D). Specific antibody levels in blood and saliva were positively correlated (*r*=
- 0.5, *p*<0.0001).

Therefore, we analyzed how variables previously reported to be associated with systemic anti-

SARS-CoV-2 IgG antibody levels, relate to antibody levels in both the blood and the salivary

compartment. As we observed similar results among subjects who received one or two doses of

- 208 mRNA-based vaccines, they were combined into a single group (non-mRNA + mRNA  $(3d)$ ) for the
- presentation of the results. Levels of anti-spike SARS-CoV-2 IgG antibodies were higher in

210 subjects who received three doses of schedules that included mRNA-based vaccines (non-mRNA +

mRNA (3d)) compared to those observed in individuals who received three doses of schemes not

including mRNA-based vaccines (non-mRNA (3d)) (GMC BAU/mL, 95% CI, Blood: 6335,

3990−10058 *vs* 2494, 1875−3318; *p* 0.01; Saliva: 183.3, 106.5−315.6 *vs* 47.2, 27.1−82.2; *p* 0.01)

- (Figure 1A). Subjects with a greater number of exposures to SARS-CoV-2 antigens (through
- vaccination, infection or exposure) showed higher antibody concentrations than those with a lower
- number of exposures (GMC BAU/mL, 95% CI, Blood: 5586, 4237−7365 *vs* 1615, 1162−2245; *p*





264 whether saliva could be used as an alternative to blood for the determination of antibodies against

265 SARS-CoV-2.

 In this work, we investigated and compared the systemic and salivary IgG antibody responses against SARS-CoV-2 in vaccinated adults. Analysis of different variables previously reported to be related to systemic anti-SARS-CoV-2 IgG antibody levels showed similar results for blood and saliva. Higher antibody concentrations were observed in both the blood and saliva of adults who had schedules that included mRNA-based vaccines, a greater number of exposures, a shorter interval time between last antigens exposure and saliva collection and had been exposed to SARS- CoV-2. Furthermore, a positive correlation was found between systemic and salivary anti-SARS- CoV-2 IgG antibody levels, with higher salivary antibody concentrations observed in subjects with higher systemic antibody levels. However, specific antibodies were detected in 100% of blood samples and in 82% of saliva samples. Detection of specific salivary antibodies was associated with schedules that included mRNA-based vaccines, time between last exposure and sample collection, and systemic antibody concentrations. These results, together with the fact that most subjects without detectable salivary antibodies showed lower systemic antibody levels, suggest that salivary antibody detection would appear to depend on variables that influence systemic antibody levels. Therefore, although our results showed that the salivary immune response against SARS-CoV-2 in vaccinated adults largely reflects that observed at systemic levels, salivary antibody detection might be compromised in subjects presenting lower systemic antibody concentrations. This is in agreement with previously reported results showing that salivary antibody responses were mainly detected in subjects showing higher serum antibody levels [24]. However, we observed that the prevalence of salivary antibodies was high in both adults (82%) and children (81%) [12], unlike to that previously reported in unvaccinated infected subjects [11, 13, 24] but in agreement with those reported in vaccinated subjects [13, 18, 22], suggesting that multiple exposures are required to enhance systemic antibody levels and allow salivary antibody detection. Salivary antibody concentrations were also compared between vaccinated children and adults to analyze whether specific antibody responses differed within the salivary compartment. We observed

a higher salivary antibody response against SARS-CoV-2 in vaccinated children compared to

 adults. This also remained when antibody levels were compared between children and adults who had similar vaccination schedules (three doses combining mRNA and non-mRNA based vaccines) or the same number of exposures. Furthermore, when considering the same interval time between last exposure and saliva collection, children also showed higher antibody concentrations than adults. Higher antibody levels were also observed in children exposed to SARS-CoV-2 compared to unexposed adults. These results were confirmed in a multivariable linear regression analysis, showing that age, symptomatic exposure, number of vaccine doses and schedules that included mRNA-based vaccines were associated with salivary anti-SARS-CoV-2 IgG antibody levels. The biological and molecular basis for a favorable outcome after SARS-CoV-2 infection in children compared to adults is not fully understood. Several hypotheses have tried to explain the milder presentation of the disease in children, including a protective role of pre-existing cross-reactive antibodies against seasonal coronaviruses, a lower expression of the angiotensin-converting enzyme 2 (ACE2) and a less propensity to develop an exacerbated pro-inflammatory response, among others [25]. Furthermore, it is not entirely clear the relative contribution of the antibody response to SARS-CoV-2 to the favorable outcome in the pediatric population. In the current work, we showed that children had higher salivary anti-SARS-CoV-2 IgG antibody concentrations than adults. Given that mucosal immunity plays a key role in prevention and early defense against infection, being the entry route for the virus and the site of first encounter with the immune response, it is tempting to speculate that the stronger salivary antibody response observed in children could help prevent or limit infection, thus contributing to the favorable outcome observed in the pediatric population. As salivary IgG is derived primarily from circulating IgG through transudation [26] and the salivary IgG response in adults highly reflects the systemic antibody response, it is very likely that the salivary antibody response observed in children also largely reflects that present in blood. However, given that there is also some local IgG production, we cannot rule out that a difference in the local immune response mounted may also account to the observed difference in the salivary antibody response against SARS-CoV-2 between children and adults.

 Limitations of this study include the lack of information on the systemic antibody response in children, which precluded direct comparison between the systemic and salivary immune responses in children. We had no information on neutralization titers and specific IgA antibody responses in both blood and saliva. Besides, for reasons inherent to the vaccination policies in our country, adults mainly received non-mRNA based primary vaccination schedules and children only received mRNA vaccines as third doses. Therefore, a comparison could not be made with samples from adults vaccinated with three doses of mRNA vaccines or from children vaccinated with three doses of non-mRNA-based vaccines. Despite this, we observed that among subjects who received three vaccine doses, children who only received one dose of mRNA-based vaccine showed higher salivary antibody concentrations than adults who also received one or even two doses of mRNA- based vaccines, suggesting that other factors inherent to children, in addition to the vaccination schedules received, could be contributing to the higher salivary antibody response observed in children. Information about SARS-CoV-2 variants involved in the infections/exposures and their association with antibody levels was not available. However, most infections/exposures both in adults and children occurred when the only circulating variant in Argentina was Omicron. Altogether, our results showed that the salivary immune response against SARS-CoV-2 in vaccinated adults largely reflects that observed at systemic levels. However, salivary antibody detection might be compromised in subjects with low systemic antibody concentrations, which could be related to lower immune stimulation resulting from less immunogenic vaccines, fewer exposures, or excessive time since last exposure, potentially leading to false negative results compared to blood. Nevertheless, since saliva sampling is non-invasive and allows self-collection unlike blood sampling, salivary antibody determination could be performed as an initial screening to evaluate the immune response against SARS-CoV-2, and in those subjects who do not show detectable salivary antibodies, determination of antibodies in blood should be performed whenever possible. Besides, as salivary immune response is indicative of the systemic antibody response, salivary antibody determination could guide vaccination strategies through the administration of



- 2. Toh ZQ, Higgins RA, Do LAH, Rautenbacher K, Mordant FL, Subbarao K, Dohle Ket al. Persistence of SARS-
- CoV-2-Specific IgG in Children 6 Months After Infection, Australia. Emerg Infect Dis. 2021;27(8):2233-2235. doi:
- 10.3201/eid2708.210965.
- 3. Hachim A, Gu H, Kavian O, Mori M, Kwan MYW, Chan WH, et al. SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. Nat Commun. 2022;13(1):2951. doi: 10.1038/s41467-022-30699-5.
- 4. Padoan A, Cosma C, Di Chiara C, Furlan G, Gastaldo S, Talli I, et al. Clinical and Analytical Performance of
- ELISA Salivary Serologic Assay to Detect SARS-CoV-2 IgG in Children and Adults. Antibodies (Basel). 2024 Jan;13(1):6. doi: 10.3390/antib13010006.
- 5. Dowell AC, Butler MS, Jinks E, Tut G, Lancaster T, Sylla P, et al. Children develop robust and sustained cross- reactive spike-specific immune responses to SARS-CoV-2 infection. Nat Immunol. 2022;23(1):40-49. doi: 10.1038/s41590-021-01089-8.
- 6. Kim M, Cheng WA, Congrave-Wilson Z, Marentes Ruiz CJ, Turner L, et al. Comparisons of Pediatric and Adult SARS-CoV-2-Specific Antibodies up to 6 Months after Infection, Vaccination, or Hybrid Immunity. J Pediatric Infect Dis Soc. 2024;13(1):91-99. doi: 10.1093/jpids/piad107.
- 7. Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Vanichsetakul P, Thonginnetra S, Niemsorn K, et al. Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study. Vaccines (Basel). 2022 ;10(5):807. doi: 10.3390/vaccines10050807.
- 8. Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, et al. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. Nat Commun. 2022;13(1):3700. doi: 10.1038/s41467-022-31485-z.
- 9. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis. 2022;22(2):196-208. doi: 10.1016/S1473-3099(21)00462-X.
- 10. Li G, Cappuccini F, Marchevsky NG, Aley PK, Aley R, Anslow R, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Lancet. 2022;399(10342):2212-2225. doi: 10.1016/S0140- 6736(22)00770-X.
- 11. Keuning MW, Grobben M, Bijlsma MW, Anker B, Berman-de Jong EP, Cohen S, et al. Differences in systemic and mucosal SARS-CoV-2 antibody prevalence in a prospective cohort of Dutch children. Front Immunol. 2022;13:976382. doi: 10.3389/fimmu.2022.976382.

- 12. Badano MN, Duarte A, Salamone G, Sabbione F, Pereson M, Chuit R, et al. Prevalence of salivary anti-SARS-CoV-
- 2 IgG antibodies in vaccinated children. Immunology. 2023;169(3):384-387. doi: 10.1111/imm.13656.
- 13. Conti MG, Piano Mortari E, Nenna R, Pierangeli A, Sorrentino L, Frasca F, et al. SARS-CoV-2-specific mucosal
- immune response in vaccinated versus infected children. Front Cell Infect Microbiol. 2024;14:1231697. doi:
- 10.3389/fcimb.2024.1231697.
- 14. Thomas AC, Oliver E, Baum HE, Gupta K, Shelley KL, Long AE, et al. Evaluation and deployment of isotype-
- specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults. Commun Med (Lond). 2023;3(1):37. doi: 10.1038/s43856-023-00264-2.
- 15. Dobaño C, Alonso S, Vidal M, Jiménez A, Rubio R, Santano R, et al. Multiplex Antibody Analysis of IgM, IgA and
- IgG to SARS-CoV-2 in Saliva and Serum From Infected Children and Their Close Contacts. Front Immunol. 2022;13:751705. doi: 10.3389/fimmu.2022.751705.
- 16. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52):eabe5511. doi: 10.1126/sciimmunol.abe5511.
- 17. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. J Clin Microbiol. 2020;59(1):e02204-20. doi: 10.1128/JCM.02204-20.
- 18. Healy K, Pin E, Chen P, Söderdahl G, Nowak P, Mielke S, et al. Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. Med. 2022;3(2):137-153.e3. doi: 10.1016/j.medj.2022.01.001.
- 19. Darwich A, Pozzi C, Fornasa G, Lizier M, Azzolini E, Spadoni I, et al. BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? EMBO Mol Med. 2022;14(5):e15326. doi: 10.15252/emmm.202115326.
- 20. Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Ietto G, Iovino D, et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine. 2022;75:103788. doi: 10.1016/j.ebiom.2021.103788.
- 21. Badano MN, Pereson MJ, Sabbione F, Keitelman I, Aloisi N, Chuit R, et al. SARS-CoV-2 Breakthrough Infections
- after Third Doses Boost IgG Specific Salivary and Blood Antibodies. Vaccines (Basel). 2023;11(3):534. doi: 10.3390/vaccines11030534.
- 22. Ketas TJ, Chaturbhuj D, Portillo VMC, Francomano E, Golden E, Chandrasekhar S, et al. Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathog Immun. 2021;6(1):116-134. doi: 10.20411/pai.v6i1.441.

- 23. World Health Organization. Clinical management of COVID-19: living guideline (WHO/2019-
- nCoV/clinical/2023.2). Available online:<https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2023.2>
- (Accessed October 7, 2024).
- 24. Faustini SE, Jossi SE, Perez-Toledo M, Shields AM, Allen JD, Watanabe Y, et al. Development of a high-sensitivity
- ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva.
- Immunology. 2021;164(1):135-147. doi: 10.1111/imm.13349.
- 25. Falahi S, Abdoli A, Kenarkoohi A. Claims and reasons about mild COVID-19 in children. New Microbes New
- Infect. 2021;41:100864. doi: 10.1016/j.nmni.2021.100864.
- 26. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral Microbiol. 2013;5. doi: 10.3402/jom.v5i0.20401.
- 
- 
- 
- 
- 
- 













**D** 



**C** 

### **Figure legends**

**Figure 1. Systemic and salivary antibody responses against SARS-CoV-2 in vaccinated adults.**  Blood and salivary anti-SARS-CoV-2 antibody levels were analyzed in vaccinated adults according to: vaccination schedules (A), number of exposures (B), time between last exposure and sample collection (C), exposure to SARS-CoV-2 (D). IgG anti-spike antibody concentrations (BAU/mL) with geometric means are shown. Dotted line indicates the assay detection limit (4.03 BAU/mL). Subjects with detectable salivary antibodies (white circles or squares) and those without detectable salivary antibodies (black circles or squares) are shown. *p* values were determined by Mann-Whitney test.

#### **Figure 2. Comparison of salivary antibody responses against SARS-CoV-2 between**

**vaccinated children and adults.** Salivary anti-SARS-CoV-2 antibody levels were compared between vaccinated adults and children according to: vaccination schedules (A), number of exposures (B), time between last exposure and sample collection (C), exposure to SARS-CoV-2 (D). IgG anti-spike antibody concentrations (BAU/mL) with geometric means are shown. Dotted line indicates the assay detection limit (4.03 BAU/mL). *p* values were determined by Mann-Whitney test.

#### **Table 1. Characteristics of children and adults**



BBIBP-CorV (Sinopharm); BNT162b2 mRNA (Pfizer–BioNTech); mRNA-1273 (Moderna).